Yearly Archive

Yearly Archives: 2012

September 24, 2012 2 responses

Managing failure is the key to success

The pharma industry, with decadal time lines and multi-billion dollar R&D budgets, is particularly sensitive to progressing projects that should have been killed.

Occasionally failure is perfectly obvious, and the decision to kill a project is trivial.  But much more often, there is no certainty whether you are killing a future blockbuster or saving millions in wasted resources.  “Kill or continue” is a critical decision that often has to be made with little hard evidence – and made multiple times over on each project as new material data is accumulated.

The efficiency of this decision – recognizing impending failure as early as possible – is key to improving capital efficiency in the pharmaceutical industry.  Yet structural factors, as much as the quality of the team or the data that’s available, unwittingly bias this key decision in favour of continuing – often with disastrous consequences.

The key to improving capital efficiency in the pharmaceutical industry is to minimize the assymetries between a decision to kill a project or continue to invest in it

A “kill” decision, crystalizing a loss (of resource and of face), is inherently less attractive than continuing.  Even if the outlook is weakening, there is always a possibility things can be turned around – and even if it fails eventually that will probably happen on someone else’s watch.  Similarly, a “kill” decision requires active bravery, while continuing is usually the default.

Eliminating these systemic biases, making the “kill” and “continue” options feel equally attractive, and making “continue” an active decision like “kill”, is therefore the top priority for management in this industry, whether in small biotechs or global pharma companies.  Progress is being made, but it is a tough problem and radical changes are still required.


September 17, 2012 no comments

Why clinical CROs hate eCRF systems – and why you should love them

Everything from banking to government services, from shopping …

September 7, 2012 no comments

Phase 2a proof-of-clinical-concept trials: the single most important determinant of R&D efficiency in drug development

The future of the pharmaceutical industry depends on …


Yearly Archive